Well clonal hematopoiesis detection right now is really dependent on sequencing studies from peripheral blood specimens of individual humans. We don’t call them patients necessarily because clonal hematopoiesis isn’t a real disease per se. But I do think that there will be other methods that will be developed that may enhance our ability to detect and serially monitor the disease, such as cell-free DNA and maybe other measurements based on flow cytometry and different parameters of blood measurement...
Well clonal hematopoiesis detection right now is really dependent on sequencing studies from peripheral blood specimens of individual humans. We don’t call them patients necessarily because clonal hematopoiesis isn’t a real disease per se. But I do think that there will be other methods that will be developed that may enhance our ability to detect and serially monitor the disease, such as cell-free DNA and maybe other measurements based on flow cytometry and different parameters of blood measurement.
Well, how to manage clonal hematopoiesis right now is really the big question. Is it a benign condition and we should just monitor it and/or maybe even ignore it? Is it beneficial for some conditions and detrimental to others? I think what’s emerging is the need to stratify individuals with clonal hematopoiesis beyond just the detection. That is identifying individuals at high risk, either of progressing to an actual blood cancer or having severe manifestations in other non-cancer conditions. There are several scores that have been developed based on multi-parameter integration, and time will tell how useful those will be clinically. But more importantly, I think they will help guide us into thinking about patients for whom an intervention is actually warranted, and that’s the exciting area of the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
